{"result": "(\"entity\"<|>HIPERCOLESTEROLEMIA FAMILIAR<|>EVENT<|>Hipercolesterolemia familiar is a genetic disorder characterized by elevated levels of LDL cholesterol from birth, due to mutations in the LDL receptor, affecting approximately one in 500 individuals in heterozygous form.)\n##\n(\"entity\"<|>APOLIPOPROTEÍNA E<|>PERSON<|>Apolipoproteína E is a protein crucial for the catabolism of lipoproteins, with mutations leading to disorders such as hypercholesterolemia.)\n##\n(\"entity\"<|>XANTOMAS<|>EVENT<|>Xantomas are deposits of cholesterol that can occur in tendons and skin, often associated with hyperlipidemic disorders.)\n##\n(\"entity\"<|>DISLIPIDEMIA ATROGÉNICA<|>EVENT<|>Dislipidemia aterogénica is a condition characterized by a set of anomalies related to insulin resistance, often seen in type 2 diabetes mellitus.)\n##\n(\"entity\"<|>DIABETES MELLITUS TIPO 2<|>EVENT<|>Diabetes mellitus tipo 2 is a chronic condition that affects the way the body processes blood sugar (glucose), often associated with dislipidemia.)\n##\n(\"entity\"<|>ESTATINAS<|>ORGANIZATION<|>Estatinas are a class of drugs used to lower cholesterol levels in the blood, particularly effective in managing hyperlipidemia.)\n##\n(\"entity\"<|>EZETIMIBA<|>ORGANIZATION<|>Ezetimiba is a medication that reduces cholesterol absorption in the intestines, often used in conjunction with statins.)\n##\n(\"entity\"<|>INHIBIDORES DE PCSK9<|>ORGANIZATION<|>Inhibidores de PCSK9 are a class of drugs that help lower LDL cholesterol levels by inhibiting the protein PCSK9, which regulates cholesterol levels in the blood.)\n##\n(\"relationship\"<|>HIPERCOLESTEROLEMIA FAMILIAR<|>XANTOMAS<|>Xantomas are a common symptom of hypercholesterolemia familiar, indicating cholesterol deposits in tendons.<|>8)\n##\n(\"relationship\"<|>DISLIPIDEMIA ATROGÉNICA<|>DIABETES MELLITUS TIPO 2<|>Dislipidemia aterogénica is frequently associated with type 2 diabetes mellitus due to insulin resistance.<|>7)\n##\n(\"relationship\"<|>ESTATINAS<|>HIPERCOLESTEROLEMIA FAMILIAR<|>Estatinas are commonly prescribed to manage cholesterol levels in patients with hypercholesterolemia familiar.<|>9)\n##\n(\"relationship\"<|>EZETIMIBA<|>HIPERCOLESTEROLEMIA FAMILIAR<|>Ezetimiba can be added to treatment regimens for patients with hypercholesterolemia familiar when statins alone are insufficient.<|>6)\n##\n(\"relationship\"<|>INHIBIDORES DE PCSK9<|>HIPERCOLESTEROLEMIA FAMILIAR<|>Inhibidores de PCSK9 are used to further reduce LDL cholesterol levels in patients with hypercholesterolemia familiar.<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: adecuado control del colesterol LDL, con objetivos de\n               más o menos planos, amarillos, ligeramente elevados y de tamaño diverso. Generalmente                 colesterol LDL      < 70   mg/dl en caso de existencia de enfermedad cardiovascular previa y\n               dependen de una afectación del hígado o de un trastorno metabólico de los lípidos. Se                 diabetes. Para ello, disponemos de fármacos hipolipemiantes eficaces, como las estatinas,\n               originan por trastornos hiperlipidémicos hereditarios o adquiridos y son el acúmulo de ma-            y en caso de no conseguir el objetivo, podemos añadir ezetimiba o fármacos de la familia\n               crófagos espumosos en tejido conectivo dérmico y tendones donde se producen masas                     de los inhibidores de PCSK9, entre los que se encuentra alirocumab.\n               tumorales. En la hipercolesterolemia familiar aparecen xantomas tendinosos, mientras que              Referencias:\n               los xantomas palmares son habituales en la disbetalipoproteinemia. Este trastorno es raro,            • Cardona F, Alcaide J, Fernández García JC. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrino-\n                                                                                                                       logía y Nutrición; 2015. Capítulo 124. Epidemiología, diagnóstico y clasificación de las dislipemias; [citado 11 de noviembre de 2019].\n               con una frecuencia de una por cada 10.000 personas, y fundamentalmente se debe a una                    Disponible en: https://manual.seen.es/article?id=55115050-34cc-451f-99b6-4b97ac18103c.\n               homocigosis en la apolipoproteína E (apo E), presentando el genotipo apo E2 en homocigo-              • Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. Additional Contributor. 2016 ESC/EAS Guidelines for\n               sis. Dado que la apo E desempeña un papel crucial en el catabolismo de los quilomicrones                the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058.\n               y restos de lipoproteínas de muy baja densidad (VLDL), estos sujetos afectados presentan\n               elevaciones de triglicéridos y colesterol VLDL, además de quilomicrones en ayunas. Pueden             Cuál de las siguientes características no es típica de la dislipidemia aterogénica\n               presentar xantomas y depósitos de colesterol en los surcos palmares.                              25  o dislipidemia asociada a la diabetes mellitus tipo 2 (DM2)?\n               La hipercolesterolemia se caracteriza por un aumento del colesterol plasmático en ayunas\n               y niveles normales de triglicéridos. Estos niveles elevados se asocian a aumento de las               A. Descenso de niveles de HDL triglicéridos.\n               lipoproteínas de baja densidad (LDL) puesto que las LDL son las portadoras del 65-75% del             B. Descenso de niveles de colesterol HDL.\n               colesterol plasmático total, con fenotipo IIa y suero transparente. Son tres las entidades            C. Aumento de LDL pequeñas y densas.\n               primarias relacionadas con este grupo:                                                                D.  Elevación de niveles de apo B.\n               1.  Hipercolesterolemia familiar (HF). Es un trastorno genético codominante que en forma\n                   heterocigota se da aproximadamente en uno de cada 500 individuos. Se debe funda-                  COMENTARIO\n                   mentalmente a mutaciones en el receptor de LDL y hasta la fecha se han descrito más\n                   de 200 mutaciones en el receptor. Los niveles de LDL colesterol están elevados al nacer           La dislipidemia aterogénica o asociada a la DM2 constituye un conjunto de anomalías que\n                   y permanecen así durante toda la vida. En adultos no tratados, los niveles oscilan entre          muestra una estrecha relación con la resistencia a la insulina y es un fenotipo frecuente\n                   275 y 500 mg/dl, mientras que los niveles de triglicéridos y HDL permanecen normales              en la DM2 y la dislipidemia familiar combinada. Así, cuando comparamos pacientes con\n                   e incluso bajos en estos últimos. Se observan xantomas tendinosos que son depósitos               sensibilidad normal a la insulina con los resistentes a esta, se observa que estos últimos\n                   intra- y extracelulares de colesterol en los tendones. La forma homocigota de hiperco-            tienen más partículas pequeñas y densas de LDL, VLDL e IDL, lo que refleja la elevación de\n                   lesterolemia familiar tiene una frecuencia de un individuo por millón y se acompaña\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}